21h
GlobalData on MSNSuper Bowl ad for copycat weight loss drugs stokes pharma power debateControversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...
Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...
Arrowhead Pharmaceuticals, Inc. ( NASDAQ: ARWR) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis ...
17h
Hosted on MSN'King Kong' of weight-loss drugs, Mounjaro, will be available in Ireland from next weekUse precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported a larger-than-expected loss for Q1 FY2025, with earnings per share (EPS) at -$1.39, missing the forecast of -$0.39. Revenue also fell short, totaling ...
While this condition can be caused by diabetes, tissue disease and neurological disorders, which damage the nerves and blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results